CANDEL THERAPEUTICS, INC.

Analyst Reco. Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq Other stock markets 03:59:30 2024-06-04 pm EDT			Pre-market 07:49:35 am
8.035 ^USD	-4.00%		7.83	-2.55%

May. 30	FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma	MT
May. 30	Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating	23-03-31	MT
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating	22-12-09	MT
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating	22-12-07	MT
HC Wainwright Starts Candel Therapeutics at Buy With $11 Price Target	22-12-02	MT
BMO Capital Adjusts Candel Therapeutics' Price Target to $12 from $18, Keeps Outperform Rating	22-03-31	MT
BMO Initiates Candel Therapeutics With Outperform Rating, $18 Price Target	21-11-18	MT
Candel Therapeutics : Shares Rise After Analyst Recommendations	21-08-23	MT
CANDEL THERAPEUTICS : Credit Suisse Starts Candel Therapeutics at Outperform with $15 PT, Notes Potential for Improved Investor Sentiment, Valuation	21-08-23	MT
CANDEL THERAPEUTICS : UBS Starts Candel Therapeutics at Buy With $9 Price Target	21-08-23	MT
CANDEL THERAPEUTICS : Jefferies Starts Candel Therapeutics at Buy With $22 Price Target	21-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer